Caris Life Sciences, Inc.
CAI
$16.96
$0.825.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 99.50% | 321.82% | 135.92% | -8.47% | 7.61% |
| Total Depreciation and Amortization | -28.11% | -52.67% | -53.76% | -44.80% | -60.21% |
| Total Amortization of Deferred Charges | 34.91% | -68.26% | 34.88% | 347.75% | 22.33% |
| Total Other Non-Cash Items | -64.42% | 384.76% | 508.32% | 1,212.36% | 157.65% |
| Change in Net Operating Assets | -37.78% | -748.11% | 183.86% | 65.05% | 1,225.08% |
| Cash from Operations | 204.91% | 215.05% | 189.91% | 111.58% | 57.61% |
| Capital Expenditure | -284.60% | -122.27% | -288.13% | 46.45% | -54.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -284.60% | -122.27% | -288.13% | 46.45% | -104.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -81.82% | -85.71% | 11.54% | 26.67% | 72.50% |
| Issuance of Common Stock | -35.84% | 1,319.85% | 75.73% | 134,670.74% | 582.86% |
| Repurchase of Common Stock | -154.55% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -945.20% | 980.08% | -- |
| Cash from Financing | -35.88% | 1,403.98% | -24,349.43% | 528,318.60% | -99.36% |
| Foreign Exchange rate Adjustments | -350.00% | -2,800.00% | 487.50% | 675.00% | 300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 171.32% | 205.06% | 148.18% | 1,147.37% | -117.62% |